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Abstract
Background: The N-terminal SH2 domain (N-SH2) of the non-receptor tyrosine phosphatase SHP-2 is
involved both in localization of SHP-2 by recognition of phosphotyrosine (pY) peptides and self-inhibition
of SHP-2 phosphatase activity through the formation of a protein – protein interface with the phosphatase
domain. Mutations that disrupt this interface break the coupling between pY-peptide binding cleft
conformation and self-inhibition, thereby increasing both SHP-2 phosphatase activity and pY-peptide
binding affinity, and are associated with the congenital condition Noonan syndrome and various pediatric
leukemias. To better characterize the molecular process involved in N-SH2 pY-dependent binding, we
have applied explicit-solvent molecular dynamics simulations to study the closed-to-open transition of the
N-SH2 pY-peptide binding cleft.
Results: The existence of stable conformations in the left-handed helical and the extended regions of
Tyr66 φ/ψ space prevent rapid interconversion of the backbone and create a conformational switch such
that Tyr66 in a left-handed helical backbone conformation results in an open cleft and in an extended
backbone conformation results in a closed cleft. The stable conformations arise from deep, well-localized
free-energy minima in the left-handed helical and extended regions of the Tyr66 φ/ψ map. Changing the
Tyr66 backbone conformation from extended to left-handed helical induces a closed-to-open transition in
the cleft, and the reverse change in backbone conformation induces the reverse, open-to-closed transition.
In the open-cleft state, weak solvent-exposed interactions involving the sidechains of Tyr66, Asp40, Lys55,
and Gln57 serve to anchor the Tyr66 sidechain to the surface of the protein and away from the binding
cleft entrance, thereby facilitating pY-peptide access to the binding cleft.
Conclusion: The simulations point to a regulatory role for Tyr66 and surrounding residues in SHP-2
function: mutations at Tyr66, Asp40, Lys55, and/or Gln57 are predicted to break the switching mechanism
and negatively impact pY-peptide binding. This in turn would interfere with cellular localization and the
coupled SHP-2 phosphatase activity. The structurally well-defined binding cleft conformations resulting
from the switch-like transition suggest the possibility of applying structure-based methods to develop
inhibitors of N-SH2 pY-peptide binding to serve as research tools for signal transduction and precursors
to therapeutics for SHP-2-related diseases.
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Background
The ubiquitously expressed vertebrate non-transmem-
brane protein tyrosine phosphatase SHP-2 takes part in
intracellular signal transduction induced by a variety of
environmental cues and plays an important role in diverse
cellular processes [1-3]. The SHP-2 protein consists of 593
residues, with the first 213 residues comprising two SRC
homology 2 domains (SH2) and the remainder a protein
tyrosine phosphatase domain (PTP) and the C-terminal
tail. The 2.0 Å X-ray crystal structure of SHP-2 [4] reveals
that the PTP catalytic site is blocked by the formation of
an intramolecular protein – protein interface between PTP
and the N-terminal SH2 domain (N-SH2), thereby pro-
viding a structural explanation for the low baseline SHP-2
tyrosine phosphatase activity [5,6]. In addition to self-
inhibiting catalysis, N-SH2, like the second (C-terminal)
SH2 domain (C-SH2), has the capacity to selectively bind
phosphotyrosine (pY) peptides of a particular sequence
[7,8]. Thus, SHP-2 can be recruited to different regions of
the cell via the interaction of its N-SH2 or C-SH2 domains
with particular pY-peptides localized in these different
regions.
Crystal structures of N-SH2 alone, both with and without
bound pY-peptides [9,10], show an open pY-peptide
binding cleft between the EF loop (Tyr66-Gly67-Gly68)
and the BG loop (Lys89-Glu90-Lys91-Asn92). This is in
contrast to the crystal structure of the complete self-inhib-
ited protein wherein the PTP-bound N-SH2's peptide-
binding cleft is closed due to EF-loop motion and there-
fore unable to accommodate a pY-peptide (Figure 1).
These structural studies, combined with biochemical evi-
dence [5,6], imply that pY-peptide binding and disrup-
tion of the intramolecular N-SH2 – PTP interface, and
hence activation of phosphatase activity, are normally
coupled. Mutations at the protein – protein interface that
disrupt the interface leading to the active form of the pro-
tein are associated with the congenital disease Noonan
syndrome as well as childhood leukemias [11-13].
Accordingly, it may be anticipated that small-molecule
inhibitors of either SHP-2 SH2 pY-peptide binding or PTP
activity have the potential to serve as novel research tools
and as potential precursors to therapeutics. To better
understand the biochemical properties of the N-SH2
domain with the aim of developing N-SH2-specific inhib-
itors, we have used molecular dynamics (MD) simula-
tions to investigate the closed-to-open transition of the N-
SH2 pY-peptide binding cleft. Our data suggest that Tyr66
plays an important role in this conformational switching.
Results and discussion
N-SH2 pY-peptide binding cleft width in experimental 
crystal structures
The width of the pY-peptide binding cleft, formed by the
EF (residues 66–68) and BG (residues 89–92) loops, can
be characterized by the distance between the Cα atoms of
Gly67 and Asn92 (Figure 1b). In the crystal structure of
the full SHP-2 protein [PDB:2SHP] [4], which consists of
a 525-residue polypeptide comprising the two SH2
domains followed by the PTP domain and in the self-
inhibited conformation, this distance is 8.2 Å and the cleft
is in the closed conformation. In contrast, in the crystal
structure of isolated N-SH2 without bound peptide
[PDB:1AYD] [9] this distance is substantially longer at
14.3 Å, and reflects the fact that the cleft is open. Interest-
ingly, in crystal structures of N-SH2 complexed with pY
peptides, this distance assumes values of 14.8 Å
([PDB:1AYA], pY peptide = SVLpYTAVQP{NE}, amino
acids in braces are missing coordinates in the crystal), 16.2
Å ([PDB:1AYB], {SP}GEpYVNIEF{GS}), and 14.4 Å
([PBD:1AYC], {D}GGpYMDMS{KGS}) [9]. The near-
identical cleft widths in the isolated N-SH2 crystal struc-
tures both in the presence and absence of bound pY-pep-
tide imply that, when not bound to PTP, N-SH2 adopts a
conformation with an open pY-peptide binding cleft that
is pre-arranged to bind pY-peptide. The open cleft confor-
mation is thus more thermodynamically favorable than
the closed conformation when N-SH2 is not bound to
PTP, in contrast to the PTP-bound conformation in which
the cleft is closed.
Molecular dynamics simulations
Molecular dynamics (MD) simulations complement crys-
tallographic structural data by providing a direct view of
structural fluctuations and conformational changes at the
nanosecond timescale. Consequently, transitions
between two conformationally different crystal structures
of the same protein can be directly probed via simula-
tions. For example, if simulations starting from two differ-
ent crystallographic conformations converge to one of the
two conformations, it can be inferred that that sampled
conformation is more stable and that there is a low or
non-existent energy barrier for the transition. If, on the
other hand, the crystallographic conformations are main-
tained, a barrier exists that prevents the transition on the
time scale of the simulation.
To characterize the conformational properties of the N-
SH2 pY-peptide binding cleft, all-atom nanosecond-scale
explicit-solvent MD simulations at a temperature of 298 K
and pressure of 1 atm were performed on isolated N-SH2
and the full SHP-2 protein, all in the absence of pY-pep-
tide. The simulations included all protein and solvent
degrees-of-freedom and thus can be used to probe the
dynamic and thermodynamic properties of the solvated
proteins at an atomic level-of-detail. Three systems were
constructed using two x-ray crystal structures. Two systems
were of the isolated N-SH2 domain, one having an open
pY-peptide binding cleft as the starting conformation and
the second having a closed pY-peptide binding cleft. TheBMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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third system was of the full SHP-2 protein in which the
cleft is closed. Table 1 summarizes the crystal structures
used for system construction, the residue span, and the
pY-peptide binding cleft conformation for the three sys-
tems, as well as the abbreviations used in the text to
describe each system. All three systems were solvated with
water molecules and neutralizing counterions, and were
of a size such that a minimum of a 14-Å layer of water sur-
rounded the protein on all sides. The resultant concentra-
tions were 8 mM for the N-SH2 domain systems and 2
mM for the full SHP-2 system. The simulations were done
using periodic boundary conditions to prevent boundary
artifacts. Under periodic boundary conditions, the system
sees its own image in all directions and when a molecule
drifts out of one side of the system, it drifts back in from
the opposite side. Further simulation details are described
in the Methods section.
To test for equilibration of the MD simulations of the
three systems, time courses for the Cα root mean square
deviations (RMSDs) relative to the respective crystal struc-
tures as well as average system energies were calculated.
RMSD and average energy data correlate with how thor-
oughly the protein has relaxed in response to the sur-
rounding environment and how thoroughly the
environment has relaxed in response to the protein. The
two 10-ns N-SH2 simulations reach plateaus in both aver-
age energy and RMSD by 3 ns (Figures 2a and 2b) and are
thus well-equilibrated on the timescale of the simula-
tions. The fluctuation in RMSD near the end of the
1AYD:N-SH2 simulation is solely due to motion in the N-
and C-terminal residues, which are both on the opposite
face of the protein as the binding cleft. The full SHP-2 sys-
tem shows more limited convergence than the N-SH2 sys-
tems owing to its larger size, which both increases the
timescale for equilibration and hinders longer sampling
because of computational cost. Nonetheless, the simula-
tion statistics are relatively constant during the 3–5 ns
interval and show that the system has largely finished
relaxation by 3 ns (Figure 2c). Given that the RMSD and
average energy time courses reach equilibrium values by 3
ns for all three simulations, only molecular dynamics
snapshots after the 3-ns time point were used for further
analysis.
To investigate the conformational change in the pY-pep-
tide binding cleft, average structures of N-SH2 from the
1AYD:N-SH2, 2SHP:N-SH2, and 2SHP:SHP-2 MD trajec-
tories were calculated. Conformations sampled every
0.02-ns were RMS-aligned to their respective crystal struc-
SHP-2 N-SH2 crystal structures Figure 1
SHP-2 N-SH2 crystal structures. A) Crystal structure of isolated N-SH2 [PDB:1AYD] [9] showing the open pY-peptide binding 
cleft formed by the EF (red) and BG loops. B) Crystal structures of isolated N-SH2 [PDB:1AYD] (red), and N-SH2 in the full 
SHP-2 protein [PDB:2SHP] [4] (yellow). Dashed lines connect the Cα atoms of Gly67 and Asn92. Also shown are pY-peptides 
from N-SH2 – pY-peptide complexes [blue from PDB:1AYA and green from PDB:1AYB] [9]. All structures were RMS aligned 
to the Cα atoms of residues 6 to 55 of the SHP-2 crystal structure, which are structurally similar among the crystal structures. 
Molecular graphics were generated with VMD [45].BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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tures using all atoms in residues 1–108. Average coordi-
nates were then calculated for these aligned
conformations for the 3–5 ns interval of the 2SHP:SHP-2
simulation and for the 3–5 ns and 5–10 ns intervals for
the 1AYD:N-SH2 and 2SHP:N-SH2 simulations. The
1AYD:N-SH2 3–5 ns and 5–10 ns average structures both
had large Gly67 Cα – Asn92 Cα distances, consistent with
a wide pY-peptide binding cleft. Their values were 18.0
and 14.7 Å, as compared to the crystallographic distance
of 14.3 Å. In contrast, distances from the two simulations
initiated from the SHP-2 crystal structure were smaller,
consistent with a narrow cleft, and similar to the crystallo-
graphic distance of 8.2 Å. These values were 9.9 Å for
2SHP:SHP-2:3–5 ns, 10.6 Å for 2SHP:N-SH2:3–5 ns, and
11.8 Å for 2SHP:N-SH2:5–10 ns. The upward drift in the
2SHP:N-SH2 values is accounted for by changes in the BG
loop backbone conformation that bring it into consensus
with the isolated N-SH2 crystal conformation, as detailed
subsequently. Nonetheless, this N-SH2 domain system
with the closed cleft, which was constructed using the full
SHP-2 crystal structure, does not relax fully to the open
cleft conformation despite the absence of the PTP
domain.
Figure 3 illustrates the differences between average struc-
tures from all three simulations: 1AYD:N-SH2 has a differ-
ent EF loop conformation than 2SHP:N-SH2 and
2SHP:SHP-2. This difference translates to a wider cleft for
1AYD:N-SH2, despite relaxation to very similar BG loop
conformations for 1AYD:N-SH2 and 2SHP:N-SH2. The
narrower cleft in the 2SHP:N-SH2 simulation demon-
strates that the closed-to-open transition does not occur
on the nanosecond timescale, though such transitions
involving loop motion have been shown to occur on this
timescale [14]. The inability of 2SHP:N-SH2 to fully relax
to the open conformation over the course of 10 ns sug-
gests the process is not diffusion controlled. Thus, while
the crystallographic data imply that the open conforma-
tion is the preferred one (lower free-energy) for isolated
N-SH2, the molecular dynamics predict an energetic bar-
rier to the full closed-to-open transition.
Backbone φ/ψ angles for residues 55 to 101 in the crystal
structures and the average structures were calculated for a
detailed comparison of the backbone conformations that
correspond to the different pY-peptide binding-cleft
widths. Residues were classified as being in extended (E),
helical (H), left-handed helical (L), gamma (G), and II'
(2) regions of φ/ψ space (Figure 4). Of the 47 residues in
this span, 36 have the same secondary structure across
both of the crystal structures and all five of the simulation
average structures. The residues in which differences occur
are 60, 65–68, 85–86, and 90–93, with 5 of these 11 being
conformationally labile Gly residues. This set of 11 resi-
dues largely overlaps the residue ranges of the EF (residues
66–68) and BG (89–92) loops, which indicates the con-
formational variability of the two loops.
BG loop conformation depends on N-SH2 – PTP binding
Analysis of the backbone conformation of the three sys-
tems' BG loops shows that the two simulations of N-SH2
converge to a common structure resembling that from the
crystal of isolated N-SH2, whereas the crystallographic BG
loop conformation in the full SHP-2 protein is main-
tained in the simulation of the full SHP-2 protein. The
1AYD:N-SH2 3–5 ns and 2SHP:N-SH2 3–5 ns average
conformations assume the same secondary structure for
residues 90–93, EHHL, one that is nearly the same as the
isolated N-SH2 crystal structure and is maintained in the
5–10 ns interval average structures. In contrast, the
2SHP:SHP-2 3–5 ns average conformation maintains the
2SHP crystallographic secondary structure for Glu90 and
Lys91. Thus, maintenance of the PTP-bound secondary
structure of the N-SH2 BG loop (residues 89–92) requires
that N-SH2 be bound to PTP, although residues in the
vicinity of the loop (e.g. 85–86, Figure 4) can undergo
conformational changes. In the absence of this protein –
protein interface, the BG loop relaxes to a conformation
consistent with the crystallographic conformation of the
BG loop in isolated N-SH2. Interestingly, the N-SH2 BG
loop has no direct contact with PTP in the SHP-2 crystal
structure. The difference in BG loop conformations
between the PTP-bound and unbound N-SH2 states
implies conformational coupling: a preference for a par-
ticular BG loop conformation is induced by interaction of
a different portion of the N-SH2 domain with the PTP-
domain, thereby communicating the presence of the PTP-
domain to the BG loop.
Table 1: Summary of the three simulated systems
System description Crystal structure used for 
construction
Residue span pY-peptide binding cleft 
state in crystal†
Abbreviation for system
Isolated N-SH2 Isolated N-SH2 
[PDB:1AYD]
1–108 Open 1AYD:N-SH2
Isolated N-SH2 Full SHP-2 [PDB:2SHP] 1–108 Closed 2SHP:N-SH2
Full SHP-2 Full SHP-2 [PDB:2SHP] 1–525 Closed 2SHP:SHP-2
† Crystals did not have bound pY-peptide.BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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EF loop conformation correlates with the Tyr66 backbone 
conformation
Contrasting behavior is observed in the EF loop (residues
66–68, sequence YGG) where, unlike the BG loop in the
N-SH2 simulations, structural convergence does not
occur. In all three simulations the backbone conforma-
tion for Tyr66 is retained relative to that of the respective
crystals, while those of the two glycine residues (67 and
68) show more conformational flexibility (Figure 4). For
Tyr66, the 1AYD:N-SH2 average structures maintain the
crystallographic left-handed helical backbone conforma-
tion, L, whereas the 2SHP:N-SH2 and 2SHP:SHP-2 aver-
age structures maintain the crystallographic extended
backbone conformation, E. The adjacent Leu65 does
exhibit an E-to-H transition in one of the two N-SH2
domain simulations, but this is a small conformational
change as the crystallographic φ/ψ values are -113/61 for
this residue such that only a 2° change in the ψ angle is
required to effect the change in classification. These results
indicate Tyr66 to be the key difference in the two N-SH2-
domain simulations, since it is the only non-Gly residue
whose backbone conformation is both different in the
Cα RMSD and average energy vs. time Figure 2
Cα RMSD and average energy vs. time. Points represent the Cα RMSD, solid lines are the least-squares fit to the average of the 
total system potential energy calculated in 0.1-ns blocks (<TOTE>0.1 ns), and dashed lines are located at <TOTE<0.1 ns ± 2*SEM, 
where SEM is the standard-error-of-the-mean in the total energy for the 0.1-ns block as calculated from the average energies 
of the 50 successive 0.002-ns intervals in that block. The energies for each system have been offset by a constant for clarity. A) 
The N-SH2 system as constructed from the isolated N-SH2 crystal coordinates (1AYD:N-SH2). B) The N-SH2 system from 
the SHP-2 coordinates (2SHP:N-SH2). C) The entire SHP-2 protein using the SHP-2 coordinates (2SHP:SHP-2). RMSD values 
are calculated relative to the respective X-ray crystal coordinates after Cα-atom least-squares alignment.BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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two crystals and does not show conformational conver-
gence in the simulations.
Supporting the important role of Tyr66 in dictating the
conformation of the EF loop is the correlation between
the cleft-width, as measured by the Gly67 Cα – Asn92 Cα
distance (Figure 4), and the Tyr66 backbone conforma-
tion. When Tyr66 is in the extended region of φ/ψ space,
the cleft is closed and when Tyr66 is in the left-handed
helix region of φ/ψ space, the cleft is open. Thus although
six residues among the seven that compose the EF and BG
loops have different conformations in the two crystal
structures, the backbone conformation of Tyr66 appears
to be a key factor in the closed-to-open conformational
change in the pY-peptide binding cleft. This observation
motivated additional calculations to validate Tyr66 as a
conformational switch dictating the structure of the EF
loop.
Deep free-energy minima keep the Tyr66 backbone locked 
in position
To obtain a quantitative estimate of the energetics associ-
ated with the conformational change in Tyr66, free-energy
simulations were carried out using the final N-SH2
domain conformations from the 1AYD:N-SH2 and
2SHP:N-SH2 simulations. By applying restraining poten-
tials to the φ/ψ dihedrals of Tyr66, Tyr66 conformations
in the neighborhood of these final conformations were
preferentially sampled while averaging over all other pro-
tein degrees of freedom. The data were appropriately re-
weighted and combined to yield effective free-energy sur-
faces, or "potentials-of-mean-force" (PMFs), as a function
of the Tyr66 backbone conformation. These PMFs reveal
the free-energy barriers to changes in Tyr66 backbone con-
formation for solvated N-SH2 at room temperature and
atmospheric pressure.
From the PMF data, displacements of only 20 to 40
degrees in either the φ or ψ coordinate of the Tyr66 back-
bone translate to increases in free energy of 3 or more
kcal/mol (Figure 5). Thus, in the open cleft state, Tyr66 is
constrained to a small portion of φ/ψ space corresponding
to a left-handed helical conformation, and in the closed
cleft state Tyr66 is constrained to a small portion of φ/ψ
space corresponding to an extended conformation. These
deep and well-defined free-energy minima serve to lock
Tyr66 into a particular backbone conformation, thereby
explaining the lack of EF loop relaxation to a consensus
conformation in the two 10-ns molecular dynamics tra-
jectories of isolated N-SH2 (1AYD:N-SH2 and 2SHP:N-
SH2).
If indeed Tyr66 is the key residue that modulates the
closed-to-open transition of the pY-peptide binding cleft,
the fact that it is constrained to two small regions of φ/ψ
space allows it to act like a molecular switch. Intermediate
states become very unlikely because they are high in free
energy and therefore the EF loop is in either the closed or
open conformation depending on the Tyr66 backbone
conformation, and not in some intermediate state. The
PMF data are corroborated by the nanosecond-scale MD
simulations. In the case of 2SHP:N-SH2 and 2SHP:SHP-2,
Tyr66 only samples φ/ψ conformations confined to the
"closed" contours illustrated in Figure 5 while 1AYD:N-
SH2 samples conformations confined to the "open" con-
tours (Figure 6).
A change in the Tyr66 backbone conformation induces a 
conformational change in the EF loop
To test the ability of Tyr66 to act as a conformational
switch in the closed-to-open transition of the SHP-2 N-
SH2 pY-peptide binding cleft, simulations were per-
formed in which conversion between the left-handed hel-
ical (L) and extended (E) Tyr66 backbone conformations
was induced, both in the forward and backward direc-
tions. Starting with the final conformation from the 10-ns
2SHP:N-SH2 simulation, in which the Tyr66 backbone
was in the "E" conformation, an E-to-L transition was
N-SH2 average structures from molecular dynamics simula- tions Figure 3
N-SH2 average structures from molecular dynamics simula-
tions. Red: the 5–10 ns interval of the simulation of N-SH2 as 
started from the isolated N-SH2 crystal coordinates 
(1AYD:N-SH2:5–10 ns); Orange: the 5–10 ns interval of the 
simulation of N-SH2 as started from the full SHP-2 crystal 
coordinates (2SHP:N-SH2:5–10 ns); Yellow: the 3–5 ns inter-
val of the simulation of the full SHP-2 protein (2SHP:SHP-
2:3–5 ns).BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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induced over the course of 1 ns using restraining poten-
tials on the Tyr66 φ and ψ angles and following the reac-
tion path shown in Figure 7. Similarly, starting with the
final conformation from the 10-ns 1AYD:N-SH2 simula-
tion, in which the Tyr66 backbone was in the "L" confor-
mation, an L-to-E transition was induced. The basis for the
selection of this path, versus the more direct path between
the two states, was its energetic accessibility as judged by
the conformational energies of the CHARMM backbone
force field as included in Figure 7. These two sets of simu-
N-SH2 crystallographic and simulation-average secondary structures and Gly67 Cα – Asn92 Cα distances Figure 4
N-SH2 crystallographic and simulation-average secondary structures and Gly67 Cα – Asn92 Cα distances. Secondary-structure 
that is the same in all of the crystal and simulation structures is in plain text, secondary-structure corresponding to that in the 
isolated N-SH2 crystal is in bold, secondary-structure corresponding to that in the full SHP-2 crystal is in bold italics, and sec-
ondary structure corresponding to neither crystal structure is in bold underline. Vertical lines denote the spans of the EF (res-
idues 66–68) and BG (residues 89–92) loops. The φ/ψ diagram was generated using the distribution of non-Gly, non-Pro 
backbone angles in a high-resolution x-ray crystal data set of 500 proteins [46]. The data were binned in 15° × 15° intervals, 
the natural logarithm of the histogram counts were taken, and contours have been drawn every 2 units. "E" = extended, "H" = 
helix, "L" = left-handed helix, "G" = gamma, and "2" = II'.BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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lations directly test whether an induced change in the
backbone of Tyr66 can cause a transition between the
closed and open states of the pY-peptide binding cleft.
Average conformations calculated from 50 snapshots
spaced 0.2 ps apart, both at the beginning and end of each
of the two induced transitions, reveal the direct effect that
the E-to-L and L-to-E Tyr66 conformational changes have
on pY-peptide binding cleft width. The Tyr66 E-to-L tran-
sition causes a closed-to-open transition in the binding
cleft and the L-to-E transition causes an open-to-closed
binding cleft transition. After alignment of the pair of
average structures from the E-to-L transition using the Cα
atoms of the structurally invariant residues 6 to 55 (Cα
RMSD 0.44 Å), the Cα atoms of all three residues in the EF
loop have moved away from the center of the cleft (Figure
N-SH2 Tyr66 φ/ψ free-energy surfaces at 298 K and 1 atm Figure 5
N-SH2 Tyr66 φ/ψ free-energy surfaces at 298 K and 1 atm. The open cleft conformation correlates with left-handed helical 
Tyr66 φ/ψ geometry and the closed cleft conformation correlates with extended Tyr66 φ/ψ geometry. Contours are every 1 
kcal/mol.BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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8a). The average position of Tyr66 Cα has been displaced
by 2.7 Å, Gly67 by 2.8 Å, and Gly68 by 4.7 Å. The same
alignment using the average structures from the endpoints
of the L-to-E transition (0.37 Å Cα RMSD for residues 6 to
55) reveals the opposite motion, with the Cα atoms of all
three residues moving toward the center of the cleft (Fig-
ure 8b). The average position of Tyr66 Cα has been dis-
placed by 2.4 Å, Gly67 by 1.8 Å, and Gly68 by 5.5 Å. These
data provide direct evidence that Tyr66, and in particular
its backbone conformation, acts as a conformational
switch that can control the relative positioning of the EF
loop and thereby effect the closed-to-open binding cleft
transition.
The role of the Tyr66 sidechain
Visual analysis indicates sidechain – sidechain interac-
tions involving Tyr66 help to anchor the open form of the
EF loop and pull the sidechain away from the entrance to
the wide pY-peptide binding cleft. In contrast, in the
closed form this sidechain has no interactions with other
Tyr66 φ/ψ distributions in the three simulations Figure 6
Tyr66 φ/ψ distributions in the three simulations. Data are taken at 0.02-ns intervals and span the full lengths of the simulations, 
which were 10 ns for 1AYD:N-SH2 and 2SHP:N-SH2, and 5 ns for 2SHP:SHP-2.BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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parts of the protein and partially occludes the entrance to
the narrow cleft (Figure 9). This difference in sidechain
positioning and interactions is due not only to the differ-
ences in Tyr66 backbone conformation, and hence EF
loop position, but also to a difference in the χ1 dihedral of
the residue's sidechain. Due to the sp2-hybridized Cγ and
the internal symmetry of the sidechain, Tyr66 has two
equivalent minima at χ2 = ± 90°. Therefore, when the
sidechain is in a local minimum, only φ, ψ and χ1 are
required to denote its geometry.
For a three-fold rotation like χ1, local minima exist at ide-
alized values of -60°, 60°, and 180°. Crystallographically,
in the open conformation [PDB:1AYD] χ1/χ2 = -65.2°/
88.7°, and in the closed conformation [PDB:2SHP] χ1/χ2
= -165.3°/-83.4°. Thus, with the cleft open (Figure 9a) χ1
Reaction path for the interconversion of Tyr66 between the extended (E) and left-handed helical regions (L) of φ/ψ space Figure 7
Reaction path for the interconversion of Tyr66 between the extended (E) and left-handed helical regions (L) of φ/ψ space. The 
adiabatic in vacuo energy surface for the alanine dipeptide as modeled by the CHARMM all-atom force field is represented as 
contours, with isoenergetic lines every 1 kcal/mol for the first (lowest) 8 kcal/mol.BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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exists in the -60° minimum and with the cleft closed (Fig-
ure 9b) χ1 is in the 180° minimum. The combination of
the open EF loop conformation due to the left-handed
helical Tyr66 backbone and the χ1 angle in the -60° min-
imum pins the Tyr66 sidechain to the surface of the N-
SH2 domain (Figure 1a). Its close proximity to other sur-
face amino acids enables the formation of hydrogen
bonding and π-stacking with two other sidechains,
thereby reinforcing the open conformation. In particular,
in the crystallographic open form Tyr66 acts as a hydro-
gen-bond donor with respect to Asp40 and participates in
π-stacking with Gln57 (Figure 9a).
The interactions involving Tyr66 appear to be unique to
SHP-2 and the closely related SHP-1. BLAST [15] align-
ment of the SHP-2 N-SH2 sequence shows that other
homologous human SH2 domains do not have a tyrosine
residue at this position, though they sometimes possess
one or both subsequent glycine residues, and BLAST
search of the 11-residue span with the YGG sequence in its
middle yields only SHP-2 and SHP-1. Such lack of homol-
ogy suggests a potentially unique role of Tyr66 in the
SHPs.
The stability of the χ1 angle and its correlation with the
state of the EF loop is evidenced in the MD trajectories.
The trajectory of isolated N-SH2 in which the EF loop is in
the open conformation (1AYD:N-SH2) maintains crystal-
lographically-consistent χ1 values in the -60° minimum.
Likewise, the trajectories of the N-SH2 domain in which
the EF loop is in the closed conformation (2SHP:N-SH2
and 2SHP:SHP-2) sample χ1 values in the 180° minimum
(Figure 10). Surprisingly, unlike the trajectories of the iso-
lated N-SH2 domain in which χ1 exclusively samples the
crystallographic minimum, the trajectory of the full SHP-
2 protein sees a fluctuation from its crystallographic min-
imum to the other crystallographic minimum and back
again. This conformational fluctuation suggests that
though χ1 is involved in the closed-to-open transition, it
is comparatively labile with respect to the backbone con-
formation of Tyr66 φ/ψ, which by itself is able to cause EF
loop motion between the closed and open states and stays
locked in either the extended or left-handed helical state
for the full duration of the 10-ns N-SH2 and 5-ns SHP-2
molecular dynamics trajectories. This sidechain mobility
is also evident in the simulation in which the open-to-
closed transition is induced. There, as forces applied to the
Tyr66 backbone induce the L-to-E backbone transition, χ1
Average structures from the first and last 10-ps intervals of the 1-ns Tyr66 backbone E-to-L and L-to-E induced transitions Figure 8
Average structures from the first and last 10-ps intervals of the 1-ns Tyr66 backbone E-to-L and L-to-E induced transitions. 
Structures with the Tyr66 backbone in the "E" conformation are in yellow and in the "L" conformation are in red. Average 
structures were calculated after all-atom RMS alignment of all snapshots with respect to the relative crystal structure. The 
average structures have been RMS aligned to each other using the Cα atoms of the structurally invariant residues 6 to 55. A) 
The E-to-L transition as performed from the last snapshot from the 10-ns 2SHP:N-SH2 molecular dynamics simulations. B) The 
L-to-E transition as performed from the last snapshot from the 10-ns 1AYD:N-SH2 molecular dynamics simulation.BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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spontaneously transitions from the -60° minimum to the
180° minimum.
The simulation of isolated N-SH2 started from the open-
cleft isolated N-SH2 crystal structure shows the Tyr66 –
Asn40 sidechain – sidechain hydrogen bonding and the
Tyr66 – Gln57 π-stacking as in that crystal structure. Addi-
tionally, Tyr66 – Lys55 sidechain – sidechain hydrogen
bonding is observed; this interaction is consistent with the
crystal structure because crystallographically these
sidechains are in close proximity, though atoms beyond
Lys Cδ are missing crystal coordinates, presumably due to
conformational flexibility (Figure 9a). The simulation
data also reveal the fluctuating nature of these sidechain –
sidechain interactions. For example, Gln57 alternates
between π-stacking and hydrogen bonding with the Tyr66
sidechain. Asp40 during the first 5-ns goes back and forth
between direct and water-mediated hydrogen bonding
with Tyr66 and drifts out of hydrogen bonding distance
during the last 5-ns. And Lys55 forms both direct and
water-mediated hydrogen bonding networks with the
Tyr66 sidechain over the full 10 ns. Taken separately, the
Tyr66 interactions with the three sidechains from Asp40,
Lys55, and Gln57 are transient and therefore weak. How-
ever, when combined these residues anchor the Tyr66
sidechain to the surface of the domain and away from the
opening to the pY-peptide binding cleft.
When the Tyr66 sidechain is freed from interaction with
these three sidechains and can partially occlude the cleft,
the three sidechains themselves form a hydrogen-bonding
complex. In this complex the sidechain of Lys55 serves as
a hydrogen-bond donor to the Asp40 and Gln57
sidechains both in the SHP-2 crystal structure and the sim-
ulations (Figure 9b). As with the Tyr66 sidechain interac-
tions in the open-cleft form, direct interactions between
these three sidechains are transient in the MD simulations
started from the open-cleft N-SH2 structure. In the case of
Crystallographic conformations of Asp40, Lys55, Gln57, and Tyr66 Figure 9
Crystallographic conformations of Asp40, Lys55, Gln57, and Tyr66. A) Conformation in the isolated N-SH2 domain 
[PDB:1AYD]. B) Conformation in the full SHP-2 protein [PDB:2SHP]. π-stacking is represented by green dashes and hydrogen-
bond/salt-bridge interactions are circled in pink. The Cε and N atoms of the Lys55 sidechain are missing in 1AYD.BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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2SHP:N-SH2, the Asp40 – Lys55 hydrogen bond fluctu-
ates during the first 5 ns whereas it remains stably formed
during the last 5 ns. The Gln57 – Lys55 hydrogen bond
present at the beginning of this trajectory is lost when a
water molecule intercedes, but the interaction among the
three sidechains is maintained by the formation of a
hydrogen bond between the Gln57 and Asp40 sidechains.
Likewise, there is an interaction triad involving Asp40,
Lys55, and Gln57 in the case of 2SHP:SHP-2. However,
during the 3–4 ns interval χ1 fluctuates to the -60° mini-
mum (Figure 10), allowing the Tyr66 sidechain to form a
persistent hydrophobic interaction with the aliphatic
sidechain atoms of Lys55 and transient hydrophobic and
hydrogen bonding interactions with the sidechain of
Gln57. After this interval, χ1 reverts to its crystallographic
conformation in the 180° minimum. Thus, when the EF
loop is in its closed conformation, the fully solvent-
exposed Tyr66 sidechain is sufficiently mobile as to be
able to sample the open-cleft χ1 conformation that puts it
Tyr66 χ1 dihedral angle values as a function of time Figure 10
Tyr66 χ1 dihedral angle values as a function of time.BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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in contact with other amino acids on the N-SH2 surface
and away from the entrance to the binding cleft.
In summary, weak solvent-exposed interactions involving
the sidechains of Tyr66, Asp40, Lys55, and Gln57 are
important to the sidechain conformation of Tyr66. When
the cleft is open, Asp40, Lys55, and Gln57 all interact with
the Tyr66 sidechain and pin it to the surface of the protein
and away from the cleft opening. Conversely, when the
cleft is closed, Asp40, Lys55, and Gln57 form an interac-
tion triad, freeing the Tyr66 sidechain from being tied to
the surface of the protein and allowing it to become fully
solvent exposed and to partially occlude the cleft.
Conclusion
The SHP-2 N-SH2 Tyr66 backbone exists in two well-
defined conformations, extended or left-handed helical,
owing to the presence of free-energy barriers that encircle
small low-free-energy regions in φ/ψ space. Conversion
from one backbone conformation to the other leads to
motion of the N-SH2 EF loop and a change in the width
of the pY-peptide binding cleft between the EF and BG
loops. Thus, with two well-defined positions that control
the position of the EF loop, Tyr66 acts as a conformational
switch that determines the state of the binding cleft as
either closed or open. With an extended backbone confor-
mation at Tyr66, the binding cleft is closed and consistent
with the self-inhibited SHP-2 conformation in which N-
SH2 and PTP form a protein – protein interface. Con-
versely, with a left-handed helical backbone conforma-
tion at Tyr66, the binding cleft becomes open, N-SH2 is
able to localize SHP-2 to a particular region of the intrac-
ellular space via pY-peptide binding, and the PTP catalytic
site is exposed and phosphatase activity increases.
Such conformational switching is in contrast to another
possible scenario in which a continuum of Tyr66 back-
bone, and hence EF loop, conformations exists. In such a
case, rigidification of the binding cleft into either the
closed or open state would be associated with an entropic
cost and hence a free-energy penalty. pY-peptide binding
necessarily must be relatively weak so as to be readily
reversible, as required for its role in intracellular signal
transduction [16]. This is reflected in the interface
between N-SH2 and pY-peptides, wherein only the por-
tion of the pY-peptide that is in between the BG and EF
loops is buried to a significant extent. The rest of the pY-
peptide forms a relatively flat interface with N-SH2, in
contrast to strong protein – peptide binding interactions
in which a significant portion of peptide is deeply buried
in the protein [17]. If in addition to burying only a small
portion of the peptide, significant loop entropy must also
be overcome for pY-peptide binding, the interaction
would be weaker still and this might negatively impact the
ability of N-SH2 to mediate SHP-2 localization and acti-
vation. Consequently, we predict a Tyr66Gly mutation
would significantly weaken the ability of N-SH2 to bind
pY-peptides.
A possible binding mechanism is suggested by the transi-
tion in Tyr66 χ1 conformation in the simulation of the full
self-inhibited SHP-2 protein. The sidechain transition
from the crystallographic closed-cleft χ1 minimum to the
open-cleft χ1 minimum and back again shows that this
sidechain does not always occlude the entrance to the
binding cleft when N-SH2 is bound to PTP. pY-peptide
could form an initial contact between its phosphotyrosine
and immediately adjacent residues and the surface of N-
SH2 corresponding to the pY, pY-1, and pY+1 positions.
This initial contact would then be followed by secondary
pY-peptide contact with the EF and BG loops that was
facilitated by spontaneous fluctuation of the Tyr66
sidechain away from its cleft-occluding position and into
contact with Lys55 and Gln57. The secondary contact
would serve to open the pY-peptide binding cleft, thereby
securing the full N-SH2 – pY-peptide binding interaction,
inducing conformational changes in the EF and BG loops
(neither of which have direct contacts with the PTP
domain), and leading to loss of the N-SH2 – PTP interface
and exposure of the PTP catalytic site. At this point, the
Tyr66 sidechain would be pinned away from the binding
cleft entrance by the formation of interactions with Asp40
as well as Lys55 and Gln57.
Such interactions involving Tyr66 as a conformational
switch also suggest a possible role for this and surround-
ing residues in the regulation of SHP activity and cellular
localization. Interactions with environmental factors,
such as ions or other peptides, that impact the conforma-
tion of Tyr66 would facilitate either opening or closing of
the pY-peptide binding cleft. Such changes would thereby
favor or disfavor binding leading to alterations in the
phosphatase activity and to cellular localization. While
such a role is speculative, the present results suggest muta-
tions that may be used to experimentally investigate this
hypothesis. Mutations at Tyr66 to amino acids with large
sidechains that cannot form hydrogen-bond/salt-bridge
and/or π interactions may destabilize the open conforma-
tion in which Tyr66 sidechain interactions help to keep
the sidechain away from the binding cleft entrance,
thereby weakening peptide binding. Similarly, mutation
of Asp40, Lys55, and/or Gln57 to Ala would weaken the
ability of these residues to pin Tyr66 to the protein surface
and away from the binding site entrance, and again
adversely affect pY-peptide binding, and therefore cellular
localization and phosphatase activation.
The fact that the EF loop position is well-defined is fortu-
itous from an inhibitor-design perspective, as the open
conformation, which is thermodynamically more favora-BMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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ble based on the crystallographic data, can be targeted
using structure-based inhibitor-design methods without
complications due to the effects of EF-loop entropy and
induced fit on small-molecule binding. Recent work on
the pY-peptide binding-specificities of SHP-1 and SHP-2
suggests that the EF loop – BG loop cleft confers specifi-
city, thus it may be possible to develop inhibitors target-
ing the cleft that not only block pY-peptide binding, but
also preferentially do so for SHP-2 versus SHP-1 [18].
Such inhibitors can serve as research tools in the investi-
gation of leukemia- and Noonan syndrome-associated
SHP-2 mutants that have lost the ability to form the N-
SH2 – PTP interface characteristic of the self-inhibited
wild-type SHP-2. These mutants have constitutive high
phosphatase activity [19,20] and increased N-SH2 pY-
peptide binding affinity [21,22]. SHP-2 N-SH2 inhibitors
would be useful in probing the importance of increased
localization versus increased phosphatase activity in these
mutants, and would also have the potential to serve as
precursors to therapeutics.
Methods
Construction of missing crystal coordinates
The SHP-2 crystal structure was prepared for MD simula-
tions by constructing missing residues, reverting mutated
residues to their wild-type identities, and optimally deter-
mining hydrogen atom positions and Asn, Gln, and His
sidechain orientations. The crystal structure of the entire
self-inhibited SHP-2 phosphatase [PDB:2SHP], lacks
coordinates for residues 1, 156 to 160, 236 to 245, 295 to
301, and 313 to 323. The crystal structure of the catalytic
domain of SHP-1 [23], the closest homolog of SHP-2,
could not be used for modeling the missing SHP-2 resi-
dues due to low homology and gap regions after PTP
sequence alignment and the lack of Protein Data Bank
coordinates for the SHP-1 SH2 domains. Instead, loop
modeling [24] as implemented in the MODELLER 8v1
software [25] and consisting of 100 independent simu-
lated-annealing runs for each span of missing residues
was applied. This was done in an iterative fashion, such
that residue 1 was modeled first, and the best conforma-
tion based on MODELLER energy was chosen as the start-
ing model for modeling of the 156 to 160 residue span,
and so on. Missing residue spans were sufficiently distant
from each other in the structure so as to allow this
approach.
After completion of loop modeling, the missing sidechain
of Lys235 was reconstructed in its most probable confor-
mation based on protein structural database statistics
[26]. Also, the three mutations in the crystal structure –
Thr2Lys, Phe41Leu, and Phe513Ser – were reverted to
their wild-type identities. Like Lys235, Thr2 and Phe41
sidechains were built using database statistics [26]. The
Phe513 sidechain was built using χ angles from the SHP-
1 catalytic domain crystal structure's Phe509, which is in
the middle of a α-helix whose sequence is conserved
between SHP-1 and SHP-2. In the SHP-2 crystal structure,
Phe513Ser results in a cavity that is occupied by a deter-
gent molecule; reversion to the wild-type residue by mod-
eling fills this cavity. Using version c32b1 of the
CHARMM software [27], hydrogen atoms were con-
structed using CHARMM force field geometries [28], posi-
tional constraints were placed on all heavy atoms except
those of the four sidechains, all force-field energy terms
excluding electrostatics were turned on, and using force-
field default non-bonded cutoffs the geometry was opti-
mized with 1000 steps of steepest descent [29] followed
by 1000 steps of conjugate gradient minimization [30].
Finally, the Reduce software [31] was applied to deter-
mine the optimal placement of hydrogen atoms, which
includes optimization of the adjustable groups OH, SH,
NH3+, Met-CH3, and Asn, Gln and His sidechains by
rotation or flipping and, for the His sidechain, determina-
tion of protonation at the δ vs. ε position.
The crystal structure of the N-SH2 domain [PDB:1AYD]
was similarly treated to prepare it for solvation and molec-
ular dynamics. First, the Reduce software was applied. Sec-
ond, Met3 was deleted, as this crystal structure contains
only residues 3 to 103, with a Ser3Met mutation. Missing
heavy atom positions were placed using coordinates from
the complete SHP-2 modified crystal structure's N-SH2
domain after RMS alignment using the Cα atoms of resi-
dues 4 to 103, and missing hydrogen positions were built
using force field geometries. Heavy atoms with SHP-2
coordinates were harmonically restrained with a force
constant of 2 kcal*mol-1*Å-2 and other heavy atoms posi-
tions were constrained not to change. The system was
then minimized with 5000 steps of steepest descent and
5000 steps of conjugate gradient minimization and then
visualized to ensure that all geometries involving atoms
whose coordinates were taken from the modified com-
plete SHP-2 crystal structure were consistent with those
seen in crystal surveys [26].
Using the two modified crystal structures, three polypep-
tides were created for subsequent molecular dynamics
simulations. The first was the complete SHP-2 protein.
The second was the N-SH2 domain from the complete
SHP-2 protein and generated by deletion of all but resi-
dues 1–108. The last was the N-SH2 domain as created
from the N-SH2 domain-only crystal structure. All
polypeptides had positively charged amino termini and
negatively charged carboxy termini.
Construction of the solvated systems
The CHARMM all-atom force field [28] in conjunction
with the grid-based "CMAP" term for accurate backbone
energetics [32] was used to model the polypeptide, waterBMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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molecules were represented with the TIP3P water model
[33] as modified for the CHARMM all-atom force field
[34], and the SHAKE algorithm [35] was used to constrain
all bonds to hydrogen atoms to their equilibrium lengths.
Crystallographic water molecules located within 5 Å of
the polypeptide were maintained and the composite
polypeptide/crystallographic water system was mini-
mized with 5000 steps of steepest-descent minimization
[29] followed by 5000 steps of conjugate-gradient mini-
mization [30]. Next, a pre-equilibrated truncated octahe-
dron of water molecules was super-imposed on the
polypeptide such that the polypeptide was at its center.
The size of the truncated octahedron was chosen to ensure
at least a 14 Å layer of water between protein atoms and
the nearest edge. All added water molecules within 4.1 Å
of either the polypeptide or crystallographic water mole-
cules were deleted. Neutralizing counterions were placed
by random selection of added water molecules and their
replacement by sodium ions, with subsequent visualiza-
tion to confirm that no ions were placed within the pro-
tein. Three sodium ions were thus placed for the full SHP-
2 protein, and one sodium ion for each of the N-SH2 sys-
tems. Periodic boundary conditions were applied [36],
and Coulomb interactions were treated with the particle
mesh Ewald method [37], with a real-space cutoff of 10 Å,
a κ value of 0.32, order six B-spline interpolation, and a
grid spacing of ~1 Å while Lennard-Jones interactions
were truncated with force-switching [38] in the range of 8
Å to 10 Å, and the long-range correction applied to
account for the effect of Lennard-Jones interactions
beyond the truncation [36]. The nonbonded pairlist con-
tained atoms pairs separated by up to 12 Å and was
updated whenever any atom's displacement relative to its
position at the last pairlist update exceeded 1 Å. Finally,
each protein+water+ion system was minimized for 5000
steps with steepest-descent followed by 5000 steps of con-
jugate gradient prior to the MD calculations.
Molecular dynamics
Each of the three systems – 101,024 atoms and a mini-
mum dimension of 112.5 Å for the full protein; 25,244
atoms and a minimum dimension of 71.1 Å for N-SH2
from the full protein crystal structure; and 22,031 atoms
and a minimum dimension of 68.1 Å for N-SH2 from the
N-SH2-only crystal structure – was simulated in the iso-
thermal-isobaric ensemble. The system was propagated
using the 'leap-frog' algorithm to integrate the equations
of motion [39]. Temperature was maintained at 298 K by
a Nosé-Hoover heat bath [40,41] with a thermal piston
parameter of 10,000 kcal*mol-1*ps2, and pressure was
maintained at 1 atm using the Langevin piston [42] with
a piston mass of 1000 amu, a collision frequency of 10 ps-
1, and coupled to a temperature bath of 298 K. Each 5-ns
or 10-ns simulation was preceded by a 20-ps heating
interval in which the Nosé-Hoover heat bath was replaced
by rescaling of atomic velocities every 0.1 ps and in which
the Langevin piston collision frequency was 25 ps-1.
φ/ψ free-energy surface calculations
Potential of mean force (PMF) calculations were under-
taken to calculate conformational free energies of the
Tyr66 in the left-handed helical and extended regions of
φ/ψ space. Rectangular portions of both regions were sam-
pled, with the left-handed helical conformations having φ
values ranging from 30° to 110° and ψ values from 0° to
80°, and extended conformations having φ values ranging
from -110° to -20° and ψ values from 70° to 150°. To
bias sampling of Tyr66 to a particular region of φ/ψ space,
harmonic restraining potentials of the form E = k·(θ -
θmin)2 were applied to the φ and ψ dihedrals. The value of
k was incremented over the course of 20 ps: k was set to
0.003 kcal*mol-1*degree-2  for 5 ps, then increased to
0.005 for another 5 ps, then to 0.010 for another 5 ps, and
then to 0.025 for a final 5 ps. The system was then simu-
lated for 200 ps with k = 0.025 kcal*mol-1*degree-2. For
the left-handed alpha helical region, φmin/ψmin were ini-
tially set to 70°/40° and the starting conformation was
that of 1AYD:N-SH2 at 10 ns, whose Tyr66 φ/ψ values
were 74°/37°. The final snapshot from this biased simu-
lation was used as the starting point for four other simu-
lations with φmin/ψmin values of 60°/40°, 80°/40°, 70°/
30° and 70°/50° and using the same scheme that started
with  k  = 0.003 kcal*mol-1*degree-2, incremented it to
0.025 kcal*mol-1*degree-2 over 20 ps, and followed by a
200 ps trajectory. Subsequent simulations similarly
employed the final conformation from prior simulations
that had sampled a directly adjacent region in φ/ψ space,
φmin/ψmin were always a multiple of 10 degrees, and the
same  k  incrementing scheme was applied. For the
extended region, φmin/ψmin were initially set to -60°/100°
and the starting conformation was that of 2SHP:N-SH2 at
10 ns, whose Tyr66 φ/ψ values were -64°/98°. The molec-
ular dynamics methods (heat/pressure bath, integrator,
long-range truncation, etc.) were otherwise the same as for
the unrestrained molecular dynamics simulations.
Tyr66 φ/ψ values were saved every dynamics step during
the 200-ps k = 0.025 kcal*mol-1*degree-2 phase. Using the
weighted histogram analysis method [43,44], the φ/ψ
probability distributions from the simulations were prop-
erly reweighted and combined to generate free-energy sur-
faces for the 20–80 ps, 80–140 ps, and 140–200 ps
intervals. The resulting free-energy surfaces were invariant
with time, thus the combined data from the 20–200 ps
intervals was used in the analysis.
Induction of Tyr66 backbone conformational change
The same φ/ψ restraining potentials as used in the free-
energy surface calculations were applied to induce
changes in the Tyr66 backbone conformation. StartingBMC Structural Biology 2007, 7:14 http://www.biomedcentral.com/1472-6807/7/14
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conformations were the final snapshots from the 10-ns
1AYD:N-SH2 and 2SHP:N-SH2 trajectories. The change in
φmin/ψmin followed the path described in the Results and
Discussion and each subsequent simulation following
alteration of either φmin or ψmin changed by 10° used the
final snapshot from the previous simulation. k assumed
the same values as in the free-energy simulations, but was
incremented every 0.5 ps, instead of every 5 ps and was
followed by a 20-ps trajectory instead of a 200-ps trajec-
tory. 44 values of φmin/ψmin were required to span the reac-
tion path, thus the conformational change was induced
over a total of 44 * 22 ps = 968 ps. The MD protocols were
the same as for the unrestrained molecular dynamics sim-
ulations.
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